Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer.

Christoph Rochlitz; Robert Figlin; Patrick Squiban; Marc Salzberg; Miklos Pless; Richard Herrmann; Eric Tartour; Yongxiang Zhao; Nadine Bizouarne; Martine Baudin

doi:10.1002/jgm.397

Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer.

Identifier:nobleid.org/w1/20260515/C32669FD

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/C32669FD.svg?ark=w1%2F20260515%2FC32669FD)](https://nobleid.org/work/w1/20260515/C32669FD)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer.

Identifier:nobleid.org/w1/20260515/C32669FD

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/C32669FD.svg?ark=w1%2F20260515%2FC32669FD)](https://nobleid.org/work/w1/20260515/C32669FD)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work